SEARCH

SEARCH BY CITATION

References

  • Alcaraz L, Furber M, Mortimore M (2000). Adamantane derivatives. PCTInt Appl 160 pp WO 00/61569.
  • Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1S209.
  • Ames R, Nuthulaganti P, Fornwald J, Shabon U, van der Keyl H, Elshourbagy N (2004). Heterologous expression of G protein-coupled receptors in U-2 OS osteosarcoma cells. Receptors Channels 10: 117124.
  • Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S et al. (1998). Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92: 35213528.
  • Cabrini G, Falzoni S, Forchap SL, Pellegatti P, Balboni A, Agostini P et al. (2005). A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 175: 8289.
  • Carroll WA, Kalvin DM, Perez MA, Florjancic AS, Wang Y, Donnelly-Roberts DL et al. (2007). Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists. Bioorg Med Chem Lett 17: 40444048.
  • Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S (2005). Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 332: 1727.
  • Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P et al. (2005). Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114: 386396.
  • Clay WC, Condreay JP, Moore LB, Weaver SL, Watson MA, Kost TA et al. (2003). Recombinant baculoviruses used to study estrogen receptor function in human osteosarcoma cells. Assay Drug Dev Technol 1: 801810.
  • Condreay JP, Witherspoon SM, Clay WC, Kost TA (1999). Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 96: 127132.
  • Denlinger LC, Sommer JA, Parker K, Gudipaty L, Fisette PL, Watters JW et al. (2003). Mutation of a dibasic amino acid motif within the C terminus of the P2X7 nucleotide receptor results in trafficking defects and impaired function. J Immunol 171: 13041311.
  • Denlinger LC, Coursin DB, Schell K, Angelini G, Green DN, Guadarrama AG et al. (2006). Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem 52: 9951004.
  • Duplantier AJ (2003). N-alkyl-adamantyl derivatives as P2X7-receptor antagonists. PCTInt Appl 57 pp WO 03/042190 A1.
  • Feng YH, Li X, Zeng R, Gorodeski GI (2006). Endogenously expressed truncated P2X7 receptor lacking the C-terminus is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis. Nucleosides Nucleotides Nucleic Acids 25: 12711276.
  • Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Wiley JS, Britton WJ (2005). Gene dosage determines the negative effects of polymorphic alleles of the P2X7 receptor on adenosine triphosphate-mediated killing of mycobacteria by human macrophages. J Infect Dis 192: 149155.
  • Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M et al. (2006). The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176: 38773883.
  • Fonfria E, Clay WC, Levy DS, Goodwin JA, Roman S, Smith GD et al. (2008). Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue. Br J Pharmacol 153: 544556.
  • Ford R, Leroux F, Stocks M (2003). Novel adamantane derivatives. PCTInt Appl 171 pp WO 2003080579 A1.
  • Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S et al. (2001). A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276: 1113511142.
  • Gu BJ, Sluyter R, Skarratt KK, Shemon AN, Dao-Ung LP, Fuller SJ et al. (2004). An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 279: 3128731295.
  • Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85100.
  • Hibell AD, Thompson KM, Simon J, Xing M, Humphrey PP, Michel AD (2001). Species- and agonist-dependent differences in the deactivation-kinetics of P2X7 receptors. Naunyn Schmiedebergs Arch Pharmacol 363: 639648.
  • Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP et al. (2006). A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319: 13761385.
  • Humphreys BD, Virginio C, Surprenant A, Rice J, Dubyak GR (1998). Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol 54: 2232.
  • Liang L, Schwiebert EM (2005). Large pore formation uniquely associated with P2X7 purinergic receptor channels. Focus on ‘Are second messengers crucial for opening the pore associated with P2X7 receptor?’ Am J Physiol Cell Physiol 288: C240C242.
  • McQuillin A, Bass NJ, Choudhury K, Puri V, Kosmin M, Lawrence J et al. (2008). Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 14: 614620.
  • Michel AD, Fonfria E (2007). Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br J Pharmacol 152: 523537.
  • Michel AD, Thompson KM, Simon J, Boyfield I, Fonfria E, Humphrey PP (2006). Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function. Br J Pharmacol 149: 948957.
  • Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP (2007). Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol 151: 103114.
  • Michel AD, Chambers LJ, Walter DS (2008). Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol 153: 737750.
  • North RA (2002). Molecular physiology of P2X receptors. Physiol Rev 82: 10131067.
  • Ohlendorff SD, Tofteng CL, Jensen JE, Petersen S, Civitelli R, Fenger M et al. (2007). Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics 17: 555567.
  • Pelegrin P, Surprenant A (2007). Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 282: 23862394.
  • Shemon AN, Sluyter R, Fernando SL, Clarke AL, Dao-Ung LP, Skarratt KK et al. (2006). A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281: 20792086.
  • Sluyter R, Shemon AN, Hughes WE, Stevenson RO, Georgiou JG, Eslick GD et al. (2007). Canine erythrocytes express the P2X7 receptor: greatly increased function compared with human erythrocytes. Am J Physiol Regul Integr Comp Physiol 293: R2090R2098.
  • Smart ML, Gu B, Panchal RG, Wiley J, Cromer B, Williams DA et al. (2003). P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem 278: 88538860.
  • Stokes L, Jiang LH, Alcaraz L, Bent J, Bowers K, Fagura M et al. (2006). Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br J Pharmacol 149: 880887.
  • Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735738.
  • Wiley JS, Dao-Ung LP, Li C, Shemon AN, Gu BJ, Smart ML et al. (2003). An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 278: 1710817113.
  • Young MT, Pelegrin P, Surprenant A (2006). Identification of Thr283 as a key determinant of P2X7 receptor function. Br J Pharmacol 149: 261268.
  • Young MT, Pelegrin P, Surprenant A (2007). Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol 71: 92100.